Global Guillain-Barré Syndrome Treatment Market 2019-2023 - Recent Approvals of Novel Immunoglobulins from Regulatory Bodies Are Expected to Propel Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 6, 2018--The “Global Guillain-Barré Syndrome Treatment Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The Guillain-Barré syndrome treatment market is projected to register a CAGR of more than 5% by 2023.
The trend of strategic alliances to help market grow at a flourishing rate. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barré syndrome. These alliances will enhance the R&D activities of new drugs for the management of Guillain-Barré syndrome.
Immunoglobulins are the first line treatment of Guillain-Barré syndrome. The recent approvals of novel immunoglobulins from regulatory bodies are expected to propel the growth of the global Guillain-Barré syndrome treatment market during the forecast period.
Currently there is no cure for Guillain-Barré syndrome. The goal of the available treatments is to provide relief from the symptoms of disease. Although the intravenous immunoglobin therapy is more convenient and widely available, it has certain side effects. Hence, some physicians are strongly inclined toward other available plasma exchange procedures for the treatment of Guillain-Barré syndrome.
Key PlayersCSL Grifols Octapharma Shire Kedrion
1. Executive Summary
2. Scope of the Report
3. Market Landscape
4. Market Sizing
5. Five Forces Analysis
6. Market Segmentation by Product
7. Customer Landscape
8. Geographic Landscape
9. Decision Framework
10. Drivers and Challenges
12. Vendor Landscape
13. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/5d6fw5/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181206005678/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/06/2018 11:44 AM/DISC: 12/06/2018 11:44 AM